Paul Saladino· MD
it's super expensive I think they're in thousands of dollars a month so and they're only approved for a very specific group of people people if I remember correctly
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
it's super expensive I think they're in thousands of dollars a month so and they're only approved for a very specific group of people people if I remember correctly
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
the pcsk9 story has been a multi billion dollar battle that has given rise to relatively moderate uptake of those drugs could argue that's just due to the cost of the drug it's also the fact that yeah it's a relative cost issue going up against statins so switching people and all this sort of thing but it's not been it's caused a sort of downward pressure on people's enthusiasm for doing cardiovascular or drug discovery just
same problem as pcs9 inhibitor it's a $500 a month drug okay yep so again we' we' we'd have every look honestly at this point like if money were were no issue you'd probably just be on pcs9 Inhibitors aetam and um and bempedoic acid
it's a $500 a month drug in the in the United States it's cheaper outside of this country so everything's better out of the US when it comes to drug pricing but in the US you're talking about 500 bucks a month for that drug if it's not a if it's not covered by your insurance company right